Skip to main content
    G

    Gain Therapeutics Inc (GANX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.18
    +0.24 (+25.51%)

    Market Cap: $46.31M

    Last updated: Nov 17, 2026 at 4:42 PM ET

    Gain Therapeutics Inc (GANX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Gain Therapeutics (GANX) has a market cap of $46.31M and an enterprise value of $34.92M. Its share count is up 25.07% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 24.59% below the market cap, as cash exceeds debt.

    Market Cap$46.31M
    Enterprise Value$34.92M
    Latest price (Nov 17, 2026)$1.18

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.08% in the quarter ended Sep 30, 2026 and grew 28.44% a year over 2 years.

    Shares Outstanding43.77M
    Shares Change (YoY)+25.07%
    Shares Change (QoQ)+2.08%
    Share Count Growth (2Y CAGR)+28.44%

    Valuation Ratios

    P/B Ratio5.1x
    P/TBV Ratio5.1x

    Price Statistics

    The stock is down 58.30% over 52 weeks and trades 18.06% below its 50-day average.

    Beta (1Y)1.64
    52-Week Change-58.30%
    1-Month Change-5.60%
    3-Month Change-43.00%
    6-Month Change-25.79%
    5-Year Change-83.76%
    Total Return (1Y)-58.30%
    Total Return (3Y CAGR)-24.11%
    Total Return (5Y CAGR)-33.05%
    Return vs SPY (1Y)-70.16%
    Max Drawdown (1Y)-77.51%
    Max Drawdown (3Y)-81.43%
    Sharpe Ratio (1Y)-0.80
    Correlation with SPY (1Y)0.20
    50-Day Average$1.44
    200-Day Average$1.81
    52-Week Range$0.94 to $4.34
    RSI (14 Days)48.3
    Average Volume (20 Days)729.92K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.36x current liabilities, and total debt is 0.03x shareholder equity.

    Current Ratio5.36x
    Quick Ratio5.36x
    Debt / Equity0.03x

    Returns and Efficiency

    Return on invested capital is -170.49% and return on equity is -177.15% over the last 12 months.

    Return on Equity (ROE)-177.15%
    Return on Assets (ROA)-135.90%
    Return on Invested Capital (ROIC)-170.49%
    ROA (5Y Average)-97.00%

    Scores

    GANX has a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit$4.87M
    Operating Income-$17.70M
    Pretax Income-$17.55M
    Net Income-$17.98M
    Reported EPS (TTM)-$0.42

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 76.72% of the $13.23M in total assets.

    Cash and Equivalents$11.70M
    Total Debt$308.71K
    Net Cash$11.39M
    Net Cash Per Share$0.26
    Working Capital$10.33M
    Shareholder Equity$10.15M
    Book Value Per Share$0.23
    Tangible Book Value$10.08M
    Tangible Book Per Share$0.23
    Total Assets$13.23M
    Total Liabilities$3.08M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$17.07M
    FCF Per Share-$0.39
    Depreciation and Amortization$95.97K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-14.82%
    Tangible Book Per Share Growth (2Y CAGR)-14.40%

    Revenue and profit by year

    Dividends and Yields

    GANX does not pay a dividend.

    Buyback Yield-32.42%
    Shareholder Yield-32.42%

    Peer Position

    Against 5 similar companies, GANX has the 5th highest ROIC.

    ROIC-170.49% vs -95.44% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -66.45% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About GANX

    What is GANX's market cap?

    Gain Therapeutics has a market cap of $46.31M. Its enterprise value, which adds debt and subtracts cash, is $34.92M.

    How many shares of GANX are outstanding?

    Gain Therapeutics has 43.77M shares outstanding. The count is up 25.07% from a year earlier.

    Does GANX pay a dividend?

    No. Gain Therapeutics does not pay a dividend.

    How much debt does GANX have?

    Gain Therapeutics has $308.71K of total debt and $11.70M of cash and equivalents, a net cash position of $11.39M.